AIDS: European green light for Yeytuo, the new preventive treatment against HIV from Gilead laboratory
The Committee for Medicinal Products for Human Use (CHMP), attached to the European Medicines Agency (EMA), issued a favorable opinion in July for the marketing of Yeytuo. "The EU and the European Economic Area record some 25,000 new positive cases of HIV each year," recalled Professor Jean-Michel Molina, an infectious disease specialist at the Lariboisière and Saint-Louis hospitals in Paris, quoted in the press release. This figure clearly shows "that current prevention methods do not work for all those who need them," he added, "especially for vulnerable populations."
The United States approved Yeztugo for marketing in June. Clinical trials conducted by Gilead showed a reduction in the risk of HIV transmission of more than 99.9% in adults and adolescents. While they believe this new treatment could be a game-changer in the fight against HIV, many are concerned about its accessibility and price. In June, Gilead indicated that Yeztugo would cost more than $28,000 per patient per year.
